Billionaire Weston Family Strikes $9 Billion Deal For Sycamore's Boots Pharmacy

The UK’s high-street retail landscape is on the brink of a monumental shift. Private equity powerhouse Sycamore Partners is in the final stages of selling the beloved pharmacy chain Boots to the Canadian branch of the billionaire Weston family in a blockbuster deal valued at approximately $9 billion, including debt.

This sweeping transaction is the direct fallout of a massive corporate shakeup. Following Sycamore’s recent $23.7 billion take-private buyout of Boots’ parent company, Walgreens, the firm decisively split the retail business into five distinct units. The primary goal was to streamline Walgreens' core US pharmacy operations and carve out non-core international assets. Previously plagued by scrapped sale attempts due to market instability, Boots is now officially changing hands, a move that effectively cancels its highly anticipated London stock market listing.

The asset being handed over is undeniably vast. The Weston family is acquiring Walgreens’ former international operations, inheriting a sprawling pharmacy network that spans across the UK, Ireland, Thailand, Mexico, Germany, and China.

The Weston family is famously no stranger to running massive consumer empires. As one of the wealthiest families in the UK and Canada, they command an expansive global retail portfolio. They are the driving force behind Canada's largest food retailer, Loblaw, and the owners of the ubiquitous fast-fashion giant Primark. By acquiring Boots, the Westons are executing a major return to UK high-street retail while strategically diversifying their legacy holdings into the lucrative healthcare sector.

The hefty $9 billion valuation is firmly underpinned by Boots’ recent financial renaissance. In its latest fiscal year, the pharmacy chain reported a 3.2% increase in UK revenue to £7.5 billion, while pre-tax profits soared by 25% to £337 million. This robust growth has been largely fueled by surging consumer demand for premium beauty brands and emerging weight-loss treatments, proving that Boots remains a deeply profitable cornerstone of global retail.